Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bilibili Inc (BILI) vs Heron Therapeutics Inc (HRTX) Price & Performance

Bilibili IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Bilibili Inc vs Heron Therapeutics Inc — how do they compare? Bilibili Inc trades at $17.38 (market cap $7.65B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Bilibili Inc is far larger — about 124.5× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.

BILIHRTX
Market Cap
$7.65B$61.47M
Sector
MediaHealth
52-Week High
$35.92$1.49
52-Week Low
$15.96$0.32
Enterprise Value
$5.49B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bilibili Inc

Bilibili (BILI) trades at $17.48, down 7.95% over 24 hours, reflecting bearish technical momentum. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.19 versus $0.17 expected, and revenue growth to $30.35 billion in 2025. Analyst sentiment remains overwhelmingly bullish with 20 buy ratings out of 24, supported by a $300 million share repurchase program announced June 24, 2026.

The outlook is positive given robust user engagement and advertising growth, but risks include competitive pressures and reliance on Chinese market dynamics. Valuation metrics like a P/E of 36.24 suggest premium pricing, requiring sustained execution to justify upside. Near-term focus is on Q2 2026 earnings due August 27, 2026, which could catalyze movement.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX